EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation
作者： Richard Murdoch Montgomery , Luciano de Souza Queiroz , Fabio Rogerio
DOI: 10.1590/0004-282X20150059
关键词:
摘要: We studied 36 glioblastoma cases at HC-UNICAMP from 2008 to 2012 and classified the immunohistochemical distribution of wild-type epidermal growth factor receptor (EGFR), mutated forms p53 protein isocitrate dehydrogenase-1 (IDH-1) murine double 2 (MDM2). Immunostaining findings were correlated with clinical data response treatment (surgery, chemotherapy radiotherapy). About 97% tumors primary, most them localized in frontal lobe. Mean time free or symptomatic disease radiological 7.56 7.14 months, respectively. observed a significant positive correlation between expressions MDM2, EGFR MDM2. Clinical, overall survivals also showed correlation. staining survival negative The current series provides histopathological that contribute knowledge on Brazilians.
sci-hub.se 参考文章(19)
Steven S Brem, Philip J Bierman, Henry Brem, Nicholas Butowski, Marc C Chamberlain, Ennio A Chiocca, Lisa M DeAngelis, Robert A Fenstermaker, Allan Friedman, Mark R Gilbert, Deneen Hesser, Larry Junck, Gerald P Linette, Jay S Loeffler, Moshe H Maor, Madison Michael, Paul L Moots, Tara Morrison, Maciej Mrugala, Louis Burt Nabors, Herbert B Newton, Jana Portnow, Jeffrey J Raizer, Lawrence Recht, Dennis C Shrieve, Allen K Sills, Frank D Vrionis, Patrick Y Wen, Central Nervous System Cancers Journal of The National Comprehensive Cancer Network. ,vol. 11, pp. 1114- 1151 ,(2011) , 10.6004/JNCCN.2013.0132
Rakesh K. Jain, Emmanuelle di Tomaso, Dan G. Duda, Jay S. Loeffler, A. Gregory Sorensen, Tracy T. Batchelor, Angiogenesis in brain tumours Nature Reviews Neuroscience. ,vol. 8, pp. 610- 622 ,(2007) , 10.1038/NRN2175
P Korkolopoulou, P Christodoulou, K Kouzelis, M Hadjiyannakis, A Priftis, G Stamoulis, A Seretis, E Thomas-Tsagli, MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor British Journal of Cancer. ,vol. 75, pp. 1269- 1278 ,(1997) , 10.1038/BJC.1997.216
Jan Smeitink, Metabolism, gliomas, and IDH1. The New England Journal of Medicine. ,vol. 362, pp. 1144- 1145 ,(2010) , 10.1056/NEJMCIBR0912922
Sith Sathornsumetee, David A. Reardon, Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich, Molecularly targeted therapy for malignant glioma Cancer. ,vol. 110, pp. 13- 24 ,(2007) , 10.1002/CNCR.22741
Makoto Ohno, Yoshitaka Narita, Yasuji Miyakita, Yuko Matsushita, Akihiko Yoshida, Shintaro Fukushima, Koichi Ichimura, Soichiro Shibui, Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas. Brain Tumor Pathology. ,vol. 30, pp. 224- 232 ,(2013) , 10.1007/S10014-013-0140-6
Patrick Y. Wen, Santosh Kesari, Malignant Gliomas in Adults The New England Journal of Medicine. ,vol. 359, pp. 492- 507 ,(2008) , 10.1056/NEJMRA0708126
Ping Guo, Bo Hu, Weisong Gu, Li Xu, Degui Wang, Hui-Jen Su Huang, Webster K. Cavenee, Shi-Yuan Cheng, Platelet-Derived Growth Factor-B Enhances Glioma Angiogenesis by Stimulating Vascular Endothelial Growth Factor Expression in Tumor Endothelia and by Promoting Pericyte Recruitment American Journal of Pathology. ,vol. 162, pp. 1083- 1093 ,(2003) , 10.1016/S0002-9440(10)63905-3
Lenny Dang, David W. White, Stefan Gross, Bryson D. Bennett, Mark A. Bittinger, Edward M. Driggers, Valeria R. Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C. Keenan, Kevin M. Marks, Robert M. Prins, Patrick S. Ward, Katharine E. Yen, Linda M. Liau, Joshua D. Rabinowitz, Lewis C. Cantley, Craig B. Thompson, Matthew G. Vander Heiden, Shinsan M. Su, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature. ,vol. 462, pp. 739- 744 ,(2009) , 10.1038/NATURE08617
T. A. Juratli, M. Kirsch, K. Geiger, B. Klink, E. Leipnitz, T. Pinzer, S. Soucek, E. Schrok, G. Schackert, D. Krex, The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. Journal of Neuro-oncology. ,vol. 110, pp. 325- 333 ,(2012) , 10.1007/S11060-012-0977-2